Clinical-stage biopharmaceutical company Organicell Regenerative Medicine has announced positive results from its expanded access, intermediate-size patient population trial of Zofin in patients suffering from mild to moderate Covid-19 symptoms. The drug met endpoint safety and efficacy, and was found to be well tolerated among subjects without causing adverse reactions. The company is expected to immediately submit the results to the US Food and Drug Administration to amend their approved Investigational New Drug application to perform a placebo-controlled randomised Phase II clinical trial.
Moderna and Magenta Investments, a pharmaceutical and healthcare company, have entered into a new partnership to distribute Moderna’s Covid-19 vaccine and its updated variant booster candidates to the United Arab Emirates (UAE) once approved there in 2021 and 2022. Magenta is a part of a UAE investment and industrial conglomerate.
Daiichi Sankyo is halting trials of its nafamostat inhalation formulation (DS-2319) for the treatment of Covid-19. DS-2319 is an inhaled form of nafamostat mesylate, which was being evaluated as a coronavirus treatment from March this year. The company had expected nafamostat to block the membrane fusion between the envelope of the virus that causes Covid-19 and the host plasma cell membrane, but after assessing ongoing non-clinical studies and the Phase I trial, it decided to end the programme. Nafamostat is used to treat pancreatitis and contains antiviral properties.